https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king-en.html Drugnews｜藥時事 en 2026-08-18T00:00:00.000Z Eli Lilly Sold $23 Billion in One Quarter. Why Is It Still Rushing to Buy the Next Drug King? https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king.html Drugnews｜藥時事 zh-tw 2026-08-18T00:00:00.000Z 一季狂賣 230 億美元，禮來卻急著買下一個藥王 https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization-en.html Drugnews｜藥時事 en 2026-08-17T00:00:00.000Z Revenue Jumped 39%, Yet Iovance Still Lost $47 Million: Can Cancer Cell Therapy Become a Business? https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization.html Drugnews｜藥時事 zh-tw 2026-08-17T00:00:00.000Z 營收跳增 39%，還是虧了 4,700 萬美元：癌症細胞療法翻身了？